SERPINH1 (Serpin family H member 1)

Moreover, 9 transcription factors (TFs) (like STAT1), 69 key microRNAs (miRNAs) (like hsa-miR-361-3p), and 78 long non-coding RNAs (lncRNAs) (like NEAT1) were found to have relationships with potential biomarkers, and potential biomarkers had stable binding affinity with adenosine diphosphate (ADP) and lonafarnib...Importantly, RT-qPCR confirmed higher expression of HSPA8, LMNA and SERPINH1 in CS patients. The findings suggested that HSPA8, LMNA and SERPINH1 might offer novel insights for the development of targeted therapies for CS associated with angiogenesis and ISR.

In conclusion, this study elucidates how surface chiral topology can program nanoparticle fate and immune function at the molecular level. PLP represents a paradigm of "functional stealth" polymers, showing that designing surface structures with specific biorecognition properties can simultaneously evade nonspecific clearance and activate targeted intracellular functions.

Drug sensitivity screening identified six small molecules (PD0325901, ERK-6604, paclitaxel, ribociclib, TAF1, and lapatinib) that targeted SLC12A5-related pathways. Crucially, multivariate Cox regression analysis confirmed that SLC12A5 was an independent prognostic factor (HR p = 0.04). This study established SLC12A5 as a novel biomarker for GBM, uniquely bridging molecular dysregulation, edema pathogenesis, and radiomics with implications for prognosis and targeted therapy.

HSP47 inhibition promotes immune evasion by upregulating CD155 via the TRAF2-NF-κB pathway, which impairs CD8+ T cell-mediated antitumor immunity. The combination of HSP47 inhibition with CD155/TIGIT blockade enhances therapeutic efficacy, suggesting a promising strategy for combination cancer therapies.

Thus, the aim of this review is to gather and incorporate the current state of knowledge on this topic to point out the need for persistent research and innovation in the field of identification of GC biomarkers. This will enable the opportunity for new and more effective strategies for combating GC, which will further reduce its global burden and improve patient survival.

This study provides valuable insights into the immune dynamics of HNSCC and identifies a prognostic risk model based on key immune-related genes, aiding in personalized treatment strategies. The findings offer a novel approach for precise prognostic evaluation and targeted therapy development in HNSCC, advancing clinical management and patient outcomes.

To conclude, the four-gene signature demonstrated potentials to predict OS prognostic risk. Among them, CPE targets HYOU1 and activates Hippo-YAP signal to promote OS progression by blocking PANoptosis.

These findings have deepened our current understanding of CAF-mediated mechanisms in GC, contributing to the development of precision diagnostics and therapeutics in GC.

ULP is identified as a novel natural agent that synergizes with 5-FU to suppress tumor progression, primarily by modulating the ECM. The combination treatment targets SERPINH1, inhibiting collagen-mediated ECM deposition and consequently reducing tumor cell migration and invasion.

This study reveals a new mechanism by which kaempferol inhibits CRC by targeting the O-GlcNAcylation pathway. The study results suggest that O-GlcNAc-modified Hsp47 could serve as a potential therapeutic target for CRC and propose a treatment strategy guided by flavonoid biomarkers based on the inhibition of the OGT-collagen axis.

After heat stress, the addition of 5 mg/kg of nano-selenium significantly increased the expression levels of spleen heat shock protein genes, such as HSP10, HSP47, HSP70, HSP90, antioxidant-related genes, such as glutathione peroxidase (GPx), thioredoxin reductase (Trx), superoxide dismutase (SOD1), catalase (CAT) and immune-related genes, such as tumor necrosis factor-α (TNF-α), Interleukin-1β (IL-1β), Immunoglobulin M (IgM), Complement Component 3 (C3), resulting in the improvement of antioxidant capacity and immunity, and the protection of the spleen to alleviate the damages caused by heat stress. This study provides a theoretical basis for the development of anti-heat stress feeds for rainbow trout.

Drug repositioning analysis consistently prioritized MEK inhibitors, trametinib and selumetinib, as potential therapeutic candidates across all DEG datasets. Our findings suggest that ECM remodelers may serve as therapeutic targets, and highlight MEK inhibition as a promising, yet exploratory, repurposing strategy. While these results offer a molecular foundation for future precision oncology efforts in EC, further validation through proteomic analysis, functional studies, and clinical evaluation is warranted.